Eckert & Ziegler stock sits 39.02 percent below EUR 21.50 target

Published on 10/26/2026 at 09:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The November 12 report tests EUR 78.80 million revenue estimates. Eckert & Ziegler stock costs EUR 13.11 on October 26, 2026 versus the Xetra close.

Analyst expectations and reporting date

NuWays set a EUR 21.50 target on October 19, 2026.
Third-quarter revenue is estimated at EUR 78.80 million for 2026.
Eckert & Ziegler stock trades at EUR 13.11 at 9:01 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.31 percent above the Xetra close of October 23, 2026.
The next reporting date is November 12, 2026.

Eckert & Ziegler, DE0005659700, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) trades at EUR 13.11 at Lang & Schwarz on October 26, 2026 at 9:01 a.m. CEST, 0.31 percent above the Xetra close of October 23, 2026 at EUR 13.07. The market is weighing a NuWays forecast for third-quarter revenue of EUR 78.80 million and adjusted EBIT of EUR 18.20 million, published on October 19, 2026.

What will November 12 test?

The next quarterly report is scheduled for November 12, 2026. According to Boerse Express on October 20, 2026, the publication will provide the first test of the EUR 78.80 million revenue estimate and EUR 18.20 million adjusted EBIT expectation. Those are analyst estimates, not reported company results.

Three milestones shape the setup

The recent chronology shows why profitability matters. On June 24, 2026, Eckert & Ziegler approved a EUR 0.22 dividend per share for fiscal year 2025, according to Simply Wall St. On August 14, 2026, second-quarter revenue was EUR 76.40 million, down 5.20 percent year over year, while net income rose 2.50 percent to EUR 12.00 million, the same source reported.

On October 19, 2026, TradingView carried NuWays research that kept a BUY rating and a EUR 21.50 twelve-month target. The preview expects adjusted EBIT to rise 18.20 percent year over year to EUR 18.20 million, implying a 23.10 percent margin.

Dates investors can measure

The next substantiated date is November 12, 2026, for the third-quarter financial report. The business spans Medical and Isotope Products, with applications in cancer therapy, radiometry and nuclear medicine, according to the company's investor-relations page.

Price and operating test

The contrast is clear: the analyst target is EUR 21.50, while the current Lang & Schwarz quote is EUR 13.11. The November report will show whether the projected recovery in Isotope Products profitability is visible in the reported margin.

Eckert & Ziegler was valued at EUR 817.9 million in the latest market data, while its reported revenue for the first half of 2026 was EUR 149.30 million. The company reported EUR 312.0 million of revenue and EUR 77.7 million of adjusted EBIT for fiscal year 2025, according to its investor-relations page.

Eckert & Ziegler stock was trading at EUR 13.11 at Lang & Schwarz on October 26, 2026 at 9:01 a.m. CEST, 0.31 percent above the Xetra close of October 23, 2026 at EUR 13.07. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.